Likelihood of Approval Analysis for Peripheral Neuropathy (Sensory Neuropathy)
Powered by 
Unlock hidden opportunities in the LoA industry
Overview
How likely is it that the drugs in Peripheral Neuropathy (Sensory Neuropathy) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Peripheral Neuropathy (Sensory Neuropathy) Overview
Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function.
There are different types of peripheral neuropathy, each affecting specific nerves and causing varying symptoms: Sensory neuropathy, motor neuropathy, and autonomic neuropathy.
Sensory neuropathy primarily affects sensory nerves, leading to sensations of tingling, numbness, burning, increased sensitivity to touch, sharp or stabbing pains, and difficulty with coordination and balance. It can affect the hands, feet, arms, or legs.
Motor neuropathy affects motor nerves, resulting in muscle weakness, loss of coordination, or muscle cramps.
Autonomic neuropathy involves nerves regulating involuntary bodily functions, causing symptoms like changes in blood pressure, heart rate, digestion, sweating, and bladder control.
Peripheral neuropathy can have various causes. Diabetic neuropathy is one of the most common causes, affecting individuals with uncontrolled or poorly managed diabetes. Accidents, repetitive stress injuries, or trauma can damage nerves. Certain viral or bacterial infections like Lyme disease, HIV/AIDS, or shingles can lead to neuropathy. Exposure to toxins, such as heavy metals, certain medications, or chemicals, can damage nerves. Some forms of neuropathy are inherited.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Peripheral Neuropathy (Sensory Neuropathy) LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
Reasons to Buy
- Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
- Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
- Use PTSR and LOA information and event-driven changes for your investment decisions.
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports